Cardiovascular events · people with or without existing cardiovascular disease, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in cardiovascular events compared with lower PUFA (moderate certainty).
1 finding from 1 review
Coronary heart disease mortality – CHD deaths · people with or without existing cardiovascular disease, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in coronary heart disease mortality compared with lower PUFA (low certainty).
1 finding from 1 review
Atrial fibrillation and arrhythmias · people with or without existing cardiovascular disease, men and women
It is very uncertain whether higher polyunsaturated fatty acid (PUFA) changes atrial fibrillation and arrhythmias compared with lower PUFA (very low certainty).
1 finding from 1 review
Weight (kg) · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
All‐cause mortality · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in all‐cause mortality compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Stroke · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in stroke compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in cardiovascular serious adverse events compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in withdrawals due to adverse effects compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Linear growth (length/height) Unit: cm Time frame: 3 months · children under 5 years of age
1 finding from 1 review
Mean height‐for‐age z‐score · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stuntingb · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effect: hypercalciuria As defined by trialists Time frame: 3 months · children under 5 years of age
Vitamin D (higher dose) + micronutrient(s) showed no clear difference in adverse effect: hypercalciuria As defined by trialists Time frame: 3… compared with vitamin D (lower dose) + micronutrient(s) (low certainty).
1 finding from 1 review
Hypercalcaemia · children under 5 years of age
Vitamin D (higher dose) + micronutrient(s) showed no clear difference in adverse effect: hypercalcaemia As defined by trialists Time frame:… compared with vitamin D (lower dose) + micronutrient(s) (moderate certainty).
1 finding from 1 review
Adverse effect: hyperphosphataemiab · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effect: kidney stonesb · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean GI symptom scores (during RT) · Men undergoing RT for prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acute and late GI toxicity (grade 2+) · Men undergoing RT for prostate cancer
Summary of findings: Higher bladder volume showed no clear difference in acute and late GI toxicity (grade 2+) compared with lower bladder volume (low certainty).
1 finding from 1 review
Diarrhoea (grade 2+) · Men undergoing RT for prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · Men undergoing RT for prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (at the end of · adults receiving EN via nasogastric or gastrostomy tube
It is very uncertain whether higher threshold (500 mL per six hours or greater) changes mortality (at the end of compared with lower threshold (less than 500 mL per six hours) at time of aspiration (very low certainty).
1 finding from 1 review